Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940017 · ClinicalTrials.gov registry record · Phase 4
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT00940017 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT00940017, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.
Interventions
- DRUG anidulafungin and voriconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00940017
The ClinicalTrials.gov registry entry for NCT00940017 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anidulafungin and voriconazole is the first listed.
NCT00940017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00940017 about?
NCT00940017 is a clinical study titled "A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects". The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.
What is the current status of trial NCT00940017?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2008-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00940017?
The interventions under investigation include: anidulafungin and voriconazole (DRUG).
Who is sponsoring clinical trial NCT00940017?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.